Novo Nordisk A/S’s (NVO) “Overweight” Rating Reiterated at Cantor Fitzgerald

Novo Nordisk A/S (NYSE:NVO)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They presently have a $160.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 13.31% from the company’s current price.

A number of other analysts have also recently commented on NVO. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target for the company. Argus lifted their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, June 10th. Finally, BMO Capital Markets started coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Stock Down 0.9 %

NVO stock traded down $1.29 on Monday, hitting $141.21. 1,834,654 shares of the company’s stock were exchanged, compared to its average volume of 4,502,923. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $144.50. The firm has a 50 day moving average price of $131.39 and a two-hundred day moving average price of $120.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The stock has a market cap of $633.68 billion, a P/E ratio of 48.69, a price-to-earnings-growth ratio of 1.48 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The firm had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

Large investors have recently bought and sold shares of the business. Westside Investment Management Inc. raised its holdings in Novo Nordisk A/S by 83.3% in the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after purchasing an additional 649 shares during the period. Lazard Asset Management LLC raised its holdings in Novo Nordisk A/S by 182.2% in the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after purchasing an additional 964,640 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Novo Nordisk A/S by 38.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after purchasing an additional 26,067 shares during the period. Advisor Resource Council acquired a new position in Novo Nordisk A/S in the 4th quarter worth about $997,000. Finally, Procyon Advisors LLC raised its holdings in Novo Nordisk A/S by 47.7% in the 4th quarter. Procyon Advisors LLC now owns 55,026 shares of the company’s stock worth $5,692,000 after purchasing an additional 17,783 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.